metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) | |
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) | |
trametinib plus dabrafenib | BRF113928 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -